TSC research including Research Round Up – a quarterly summary of some of the most important TSC-related research from Australia and around the world.
Dr Kate Riney and the team at Queensland Children’s Hospital are currently recruiting patients for a formal phase II/III trial of topical rapamycin (sirolimus) for facial angiofibromas. Some funding for interstate travel is available, making this trial available for eligible … Read More
Epilepsy develops in 70-90% of children with TSC and it is often resistant to medication. This study investigated the potential benefits of early (preventive) treatment with vigabatrin to prevent TSC-related seizures.
Epilepsy develops in 70-90% of children with TSC and it is often resistant to medication. This study investigated the potential benefits of early (preventive) treatment with vigabatrin to prevent TSC-related seizures.
In this first Research Round Up for 2021 we are delighted to feature three significant studies which Australian-based researchers have undertaken. Read more now
The aim of this study was to summarise the results of all available research addressing the factors associated with the development of autism spectrum disorder (ASD) in children with TSC. There were 42 suitable studies which included data for 3,542 children with TSC.
Epilepsy develops in 70-90% of children with TSC and it is often resistant to medication. This study investigated the potential benefits of early (preventive) treatment with vigabatrin to prevent TSC-related seizures.
Cannabidiol (CBD) is approved as Epidyolex in Australia. The aim of this study was to look at whether the addition of CBD to other epilepsy medications was successful in reducing the number of seizures associated with TSC.
